Skip to Main Content

Author Details

Kathryn Evans
Children's Cancer Institute, Lowy Cancer Research Centre, School of Clinical Medicine
1996
32
18
PMIDPaper TitleJournal TitlePublished Year
37140091In vivo activity of the dual PI3Kδ and PI3Kγ inhibitor duvelisib against pediatric acute lymphoblastic leukemia xenografts.Pediatr Blood Cancer2023
36989489STAT5 activation promotes progression and chemotherapy resistance in early T-cell precursor acute lymphoblastic leukemia.Blood2023
37339930In vivo activity of the dual SYK/FLT3 inhibitor TAK-659 against pediatric acute lymphoblastic leukemia xenografts.Pediatr Blood Cancer2023
33067575Quantitative phosphoproteomics uncovers synergy between DNA-PK and FLT3 inhibitors in acute myeloid leukaemia.Leukemia2021
33895784Combination efficacy of ruxolitinib with standard-of-care drugs in CRLF2-rearranged Ph-like acute lymphoblastic leukemia.Leukemia2021
33608527Author Correction: Small molecule inhibition of Dynamin-dependent endocytosis targets multiple niche signals and impairs leukemia stem cells.Nat Commun2021
32536690Examining treatment responses of diagnostic marrow in murine xenografts to predict relapse in children with acute lymphoblastic leukaemia.Br J Cancer2020
31848452Effective targeting of NAMPT in patient-derived xenograft models of high-risk pediatric acute lymphoblastic leukemia.Leukemia2020
33277497Small molecule inhibition of Dynamin-dependent endocytosis targets multiple niche signals and impairs leukemia stem cells.Nat Commun2020
31012549Preclinical activity of the antibody-drug conjugate denintuzumab mafodotin (SGN-CD19A) against pediatric acute lymphoblastic leukemia xenografts.Pediatr Blood Cancer2019
31693904Genomic Profiling of Childhood Tumor Patient-Derived Xenograft Models to Enable Rational Clinical Trial Design.Cell Rep2019
31821784A Menin-MLL Inhibitor Induces Specific Chromatin Changes and Eradicates Disease in Models of MLL-Rearranged Leukemia.Cancer Cell2019
31015346OBI-3424, a Novel AKR1C3-Activated Prodrug, Exhibits Potent Efficacy against Preclinical Models of T-ALL.Clin Cancer Res2019
30537513Lymphocyte-Specific Chromatin Accessibility Pre-determines Glucocorticoid Resistance in Acute Lymphoblastic Leukemia.Cancer Cell2018
28119366Bioluminescence Imaging Enhances Analysis of Drug Responses in a Patient-Derived Xenograft Model of Pediatric ALL.Clin Cancer Res2017
27183096Xenograft-directed personalized therapy for a patient with post-transplant relapse of ALL.Bone Marrow Transplant2016
27123491Synergism of FAK and tyrosine kinase inhibition in Ph<sup>+</sup> B-ALL.JCI Insight2016
27302164Acute Sensitivity of Ph-like Acute Lymphoblastic Leukemia to the SMAC-Mimetic Birinapant.Cancer Res2016
27528024A single nucleotide polymorphism genotyping platform for the authentication of patient derived xenografts.Oncotarget2016
27416986A review of new agents evaluated against pediatric acute lymphoblastic leukemia by the Pediatric Preclinical Testing Program.Leukemia2016
27343252Venetoclax responses of pediatric ALL xenografts reveal sensitivity of MLL-rearranged leukemia.Blood2016
25306899Overexpression of ERG in cord blood progenitors promotes expansion and recapitulates molecular signatures of high ERG leukemias.Leukemia2015
26116659AKR1C3 is a biomarker of sensitivity to PR-104 in preclinical models of T-cell acute lymphoblastic leukemia.Blood2015
25504635Evaluation of the in vitro and in vivo efficacy of the JAK inhibitor AZD1480 against JAK-mutated acute lymphoblastic leukemia.Mol Cancer Ther2015
25573381Effective targeting of the P53-MDM2 axis in preclinical models of infant MLL-rearranged acute lymphoblastic leukemia.Clin Cancer Res2015
25013123Cell and molecular determinants of in vivo efficacy of the BH3 mimetic ABT-263 against pediatric acute lymphoblastic leukemia xenografts.Clin Cancer Res2014
23426279The anti-CD19 antibody-drug conjugate SAR3419 prevents hematolymphoid relapse postinduction therapy in preclinical models of pediatric acute lymphoblastic leukemia.Clin Cancer Res2013
20813542Survival outcomes of a salvage patient population after radioembolization of hepatic metastases with yttrium-90 microspheres.J Vasc Interv Radiol2010
11100888An in vivo comparison of the kinetics of protein and lipid deposition on group II and group IV frequent-replacement contact lenses.Optom Vis Sci2000
9634963Patient-dependent and material-dependent factors in contact lens deposition processes.Adv Exp Med Biol1998
9108978Lipid and protein deposition of N-vinyl pyrrolidone-containing group II and group IV frequent replacement contact lenses.CLAO J1997
8867677Spoilation and clinical performance of monthly vs. three monthly Group II disposable contact lenses.Optom Vis Sci1996
  • 1 - 32 of 32

Recommended Authors

Oregon Health & Science University
Career Start Year 2015
Number of shared co-authors 4
Department of Pharmaceutical Sciences, St. Jude Children's Research Hospital
Career Start Year 2015
Number of shared co-authors 9
Dana-Farber Cancer Institute
Career Start Year 2015
Number of shared co-authors 3
Universite de Montreal
Career Start Year 2013
Number of shared co-authors 5
Weill Cornell Medicine and New York Presbyterian Hospital
Career Start Year 2013
Number of shared co-authors 0
Knight Cancer Institute, Oregon Health & Science University
Career Start Year 2011
Number of shared co-authors 0
Dana-Farber Cancer Institute
Career Start Year 2010
Number of shared co-authors 4
Sanford Burnham Prebys Medical Discovery Institute
Career Start Year 2009
Number of shared co-authors 1
Stanford University School of Medicine
Career Start Year 2008
Number of shared co-authors 3
University of Colorado School of Medicine
Career Start Year 2008
Number of shared co-authors 0
Knight Cancer Institute, Oregon Health & Science University
Career Start Year 2006
Number of shared co-authors 0
Dana-Farber Cancer Institute
Career Start Year 2005
Number of shared co-authors 1
Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University
Career Start Year 2004
Number of shared co-authors 8
University of Kansas Medical Center
Career Start Year 2004
Number of shared co-authors 0
Oregon Health and Science University
Career Start Year 2004
Number of shared co-authors 0
University of Parma
Career Start Year 2003
Number of shared co-authors 3
Emory University School of Medicine
Career Start Year 2003
Number of shared co-authors 2
Oregon Health & Science University School of Medicine
Career Start Year 2002
Number of shared co-authors 3
Huntsman Cancer Institute, The University of Utah
Career Start Year 2001
Number of shared co-authors 0
Princess Margaret Cancer Centre
Career Start Year 1999
Number of shared co-authors 0
Merck & Co.
Career Start Year 1998
Number of shared co-authors 8
Mayo Clinic
Career Start Year 1995
Number of shared co-authors 9
Dana-Farber Cancer Institute
Career Start Year 1995
Number of shared co-authors 10
Oregon Health and Science University
Career Start Year 1993
Number of shared co-authors 4
St Jude Children's Research Hospital
Career Start Year 1993
Number of shared co-authors 9
Moffitt Cancer Center
Career Start Year 1992
Number of shared co-authors 0
Princess Margaret Cancer Centre
Career Start Year 1989
Number of shared co-authors 0
Dana-Farber Cancer Institute
Career Start Year 1989
Number of shared co-authors 2
St. Jude Children's Research Hospital
Career Start Year 1988
Number of shared co-authors 7
University of Colorado School of Medicine
Career Start Year 1974
Number of shared co-authors 0

Collaborators

Children's Cancer Institute, Lowy Cancer Research Centre, School of Clinical Medicine
Co-authored papers 27
National Cancer Institute
Co-authored papers 17
The University of Texas Health Science Center at San Antonio
Co-authored papers 12
The University of Texas Health Science Center at San Antonio
Co-authored papers 9
Children's Cancer Institute, Lowy Cancer Research Centre
Co-authored papers 7
Children's Cancer Institute, Lowy Cancer Research Centre
Co-authored papers 6
Children's Cancer Institute, Lowy Cancer Research Centre
Co-authored papers 5
St Jude Children's Research Hospital
Co-authored papers 3
School of Clinical Medicine
Co-authored papers 3
Walter and Eliza Hall Institute of Medical Research
Co-authored papers 3
Children's Cancer Institute, Lowy Cancer Research Centre
Co-authored papers 2
Center for Data-Driven Discovery in Biomedicine, Children's Hospital of Philadelphia
Co-authored papers 2
Children's Cancer Institute, Lowy Cancer Research Centre, School of Clinical Medicine
Co-authored papers 2
St Jude Children's Research Hospital
Co-authored papers 2
Laufer Center for Physical and Quantitative Biology, Stony Brook University
Co-authored papers 2
GeneCentric Therapeutics Inc.
Co-authored papers 2
University of Washington
Co-authored papers 1
Sun Yat-sen University Cancer Center
Co-authored papers 1
Cancer Center, Texas Tech University Health Sciences Center School of Medicine
Co-authored papers 1
Co-authored papers 1
Perelman School of Medicine at the University of Pennsylvania
Co-authored papers 1
University Hospital Regensburg
Co-authored papers 1
Baylor College of Medicine
Co-authored papers 1
Northwestern University
Co-authored papers 1
Biomedicine Discovery Institute, Monash University
Co-authored papers 1
Texas Children's Cancer Center, Baylor College of Medicine
Co-authored papers 1
Greehey Children's Cancer Research Institute
Co-authored papers 1
Co-authored papers 1
University of Pennsylvania Perelman School of Medicine
Co-authored papers 1
Co-authored papers 1